Can we eliminate placebo in ALS clinical trials?
Wilson W. Bryan(The University of Texas Southwestern Medical Center), Rebecca Hoagland(University of Colorado Denver), Jessie C. Goodpasture(University of Minnesota), Scott Stromatt(University of Colorado Denver), Carmel Armon(Loma Linda University), Robert G. Miller(California Pacific Medical Center), Gareth Parry(Cambridge Health Alliance), Mark A. Ross(University of Kentucky), James R. Murphy(University of Liverpool), Jack H. Petajan(United States Institute of Peace), Richard J. Barohn(University of Missouri Health System)
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
January 1, 2003
Cited by 19
Related Papers
Genetic Epidemiology of COPD (COPDGene) Study Design
|COPD Journal of Chronic Obstructive Pulmonary Disease|2010|1.3k
Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program
|Journal of Allergy and Clinical Immunology|2007|933
The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. I. Laboratory and Epidemiologic Observations
|Clinical Infectious Diseases|1983|754
Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites
|Nature|1987|503
A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
|Annals of Neurology|2008|466